AVITA Medical (NASDAQ:RCEL) Stock

AVITA MEDICAL INC

AVITA Medical

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

AVITA Medical Inc

Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.10) by 90 percent. This is a 26.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $64.16 million which missed the analyst consensus estimate of $69.50 million by 7.69 percent. This is a 16.96 percent decrease over sales of $77.26 million the same period last year.

Earnings

Earnings Misses

News

LVLU

Lulus Fashion Lounge Q1 EPS $(0.19) Misses $(0.10) Estimate, Sales $64.16M Miss $69.50M Estimate

WIIM

DLocal shares are trading higher following a Q1 EPS and revenue beat.

Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.04) by 150 percent. This is unchanged from the same period last year. The company reported quarterly sales of $43.55 million which missed the analyst consensus estimate of $47.00 million by 7.35 percent. This is a 18.67 percent decrease over sales of $53.55 million the same period last year.

GROV

Grove Collaborative Hldgs Q1 EPS $(0.10) Misses $(0.04) Estimate, Sales $43.55M Miss $47.00M Estimate

Guidance

SHIM

Shimmick Affirms FY2025 Sales Guidance of $528.26M-$552.27M vs $448.10M Est

SKYX Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYX#NASDAQ">SKYX</a>) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $20.11 million which missed the analyst consensus estimate of $20.25 million by 0.67 percent. This is a 5.99 percent increase over sales of $18.98 million the same period last year.

Earnings Beats

SKYX

SKYX Platforms Q1 EPS $(0.09) Beats $(0.10) Estimate, Sales $20.11M Miss $20.25M Estimate

CSCO

Cisco Systems shares are trading higher after the company reported better-than-expected Q3 financial results, raised its FY25 guidance, and issued Q4 adjusted EPS guidance above estimates.

Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) sees Q2 sales of $51.000 million-$61.000 million vs $60.44 million analyst estimate.

The Beachbody Company, Inc. Class A Common Stock

BODI

Beachbody Co Sees Q2 Sales $51.000M-$61.000M vs $60.44M Est

Legal

BRKR

10x Genomics Reaches Patent Litigation Settlement With Bruker; Bruker To Pay $68M In Equal Quarterly Installments Between Q3 2025 And Q2 2026 As Well As Ongoing Royalties On Sales Of Spatial Biology Products Through Life Of Licensed Patents

Tenax Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.19) by 47.37 percent. This is a 91.03 percent increase over losses of $(3.12) per share from the same period last year.

TENX

Tenax Therapeutics Q1 EPS $(0.28) Misses $(0.19) Estimate

Crescent Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCAP#NASDAQ">CCAP</a>) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.52 by 13.46 percent. This is a 28.57 percent decrease over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $42.13 million which missed the analyst consensus estimate of $45.08 million by 6.55 percent. This is a 16.35 percent decrease over sales of $50.36 million the same period last year.

CCAP

Crescent Capital BDC Q1 Net investment income per share $0.45 Misses $0.52 Estimate, Total investment income $42.13M Miss $45.08M Estimate

Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.16) per share from the same period last year. The company reported $27.00 thousand in sales this quarter.

TLPH

Talphera Q1 EPS $(0.10) Beats $(0.14) Estimate, Sales $27.00K

The Beachbody Company, Inc. Class A Common Stock Q1 EPS $(0.84) Beats $(1.44) Estimate, Sales $72.40M Beat $64.18M Estimate

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 25 percent. This is a 66.04 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $13.14 million which beat the analyst consensus estimate of $12.05 million by 9.00 percent. This is a 0.84 percent increase over sales of $13.03 million the same period last year.

DERM

Journey Medical Q1 EPS $(0.18) Beats $(0.24) Estimate, Sales $13.14M Beat $12.05M Estimate

Shimmick Q1 Adj. EPS $(0.22) Beats $(0.25) Estimate, Sales $122.00M Beat $94.35M Estimate

Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.69) by 24.64 percent. This is a 31.58 percent increase over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $15.36 million which beat the analyst consensus estimate of $14.95 million by 2.74 percent. This is a 24.01 percent decrease over sales of $20.21 million the same period last year.

ATER

Aterian Q1 EPS $(0.52) Beats $(0.69) Estimate, Sales $15.36M Beat $14.95M Estimate

Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.73 by 6.85 percent. This is a 18.18 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $245.32 million which beat the analyst consensus estimate of $230.69 million by 6.34 percent. This is a 10.00 percent increase over sales of $223.02 million the same period last year.

HWKN

Hawkins Q4 EPS $0.78 Beats $0.73 Estimate, Sales $245.32M Beat $230.69M Estimate

Azitra plans to dose first patient in a Phase 1/2 trial in the first half of 2025 for its precision dermatology candidate ATR04-484, designed for the treatment of EGFR inhibitor-associated rash

Biotech

Events

General

AZTR

Azitra To Present Phase 1/2 Study Of ATR04-484 For EGFR Inhibitor-Associated Rash

SPIR

Spire Global Sees Q2 Adj EPS $(0.49)-$(0.42) vs $(0.47) Est; Sees Sales $18.000M-$20.000M vs $22.97M Est

SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.52) by 15.38 percent. This is a 90.74 percent increase over losses of $(4.75) per share from the same period last year. The company reported quarterly sales of $293.00 thousand which beat the analyst consensus estimate of $150.00 thousand by 95.33 percent.

SeaStar Medical Holding Q1 EPS $(0.44) Beats $(0.52) Estimate, Sales $293.00K Beat $150.00K Estimate

Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) reported quarterly losses of $(0.10) per share. This is a 66.67 percent increase over losses of $(0.30) per share from the same period last year. The company reported $233.30 million in sales this quarter. This is a 8.47 percent decrease over sales of $254.90 million the same period last year.

Comments

AVITA Medical

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL